Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Pyrintegrin

SKU: orb1307825

Description

Pyrintegrin

Research Area

Stem Cell & Developmental Biology

Images & Validation

Key Properties

CAS Number1228445-38-2
MW451.5
Purity>98%
FormulaC23H25N5O3S
SMILESOc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1
TargetIntegrin
SolubilitySoluble in DMSO (45 mg/ml)

Bioactivity

In Vivo
Pyrintegrin induces postnatal adipose tissue formation in vivo of transplanted adipose stem/progenitor cells (ASCs) and recruited endogenous cells. Pyrintegrin decreases peak proteinuria caused by puromycin aminonucleoside-induced nephropathy. Pyrintegrin-treated human adipose stem/progenitor cells (ASCs) in 3D-bioprinted scaffolds, when transplanted in the dorsum of athymic mice, yielded ectopically formed adipose tissue that expressed human PPARγ. Pyrintegrin-adsorbed collagen gel implanted in the inguinal fat pad promoted adipogenesis formed by host endogenous cells, suggesting its ability to induce in situ adipogenesis without the need for cell transplantation. Pyrintegrin (10 mg/kg; intraperitoneal injection; once; C57BL/6J mice) treatment protects mice from LPS-induced podocyte foot process effacement and proteinuria. LPS administration decreases the levels of active β1 integrin in the podocytes, which is prevented by cotreatment with Pyrintegrin .
In Vitro
Pyrintegrin decreases Runx2 and Osx via BMP-mediated SMAD1/5 phosphorylation. Pyrintegrin treatment prevents damage-induced decreases in F-actin stress fibers, focal adhesions, and active β1-integrin levels in cultured cells. Pyrintegrin stimulates human adipose stem/progenitor cells (hASCs) to differentiate into lipid-laden adipocytes by upregulating peroxisome proliferator-activated receptor (PPARγ) and CCAAT/enhancer-binding protein-α (C/EBPα), with differentiated cells increasingly secreting adiponectin, leptin, glycerol, and total triglycerides. Pyrintegrin (0-10 μM; 1 hour; hASCs) treatment inhibits BMP4-mediated phosphorylation of BMP responsive SMAD1/5 in a dose-dependent manner (IC50 of 1.14 μM) .

Storage & Handling

Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

cells, Adipogenic, C/EBPα, ECM, embryonic, Integrin, Inhibitor, inhibit, nephropathy, Pyrintegrin, podocyte-protective, PPARγ, stem, proteinuria, β1-integrin, β1 integrin
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Key Properties

No computed properties available.

Protocol Information

Available Sizes

Select a size below

5 mg
$ 190.00
25 mg
$ 350.00
DispatchUsually dispatched within 5-10 working days
Bulk Enquiry